Big physics, small doses: The use of AMS and PET in human microdosing of development drugs

Nature Reviews Drug Discovery

Volumn 2, Issue 3, 2003, Pages 233-240

  Lappin, Graham ^a   Garner, R Colin ^a  

^a Xceleron Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBON 11; CARBON 14; FLUORODEOXYGLUCOSE F 18; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; NEW DRUG; DRUG;

ALLOMETRY; ARTICLE; COMPUTER MODEL; COST; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INDUSTRY; DRUG METABOLISM; DRUG RESEARCH; GENOMICS; HUMAN; MASS SPECTROMETRY; MOLECULE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEOMICS; TOXICOLOGY; ANIMAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DESIGN; DRUG SCREENING; MAGNETIC AND ELECTROMAGNETIC EQUIPMENT; METABOLISM; PHARMACOKINETICS; REVIEW;

ANIMALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MASS SPECTROMETRY; PARTICLE ACCELERATORS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037365932     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1037     Document Type: Article

References (31)

1. Tufts Center for the Study of Drug Development. [online] (cited 03.02.2003) (2002).
2. Lowest number of launches for 10 years! CMR International Report 20, 4-5 (2002).
3. New Drug Approval Reports [online], (cited 01.02.2003) http://www.fda.gov/cder/rdmt/> (2003).
4. Bolten, B. M. and DeGregorio, T. Trends in development cycles. Nature Rev. Drug Discov. 1, 335-336 (2002).
5. Dimasi, J. A. Risks in new drug development: approval success rates for investigational drugs, Clin. Pharmacol. Ther. 69, 297-307 (2001).
6. Prentis, R. A., Lis, Y. & Walker, S. R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharmacol. 25, 387-396 (1988).
7. Bajorath, J. Integration of virtual and high-throughput screening. Nature Rev. Drug Discov. 1, 882-894 (2002).
8. Blundell, T. L., Jhoti, H & Abell, C. High-throughput crystallography for lead discovery in drug design. Nature Rev Drug Discov. 1, 45-54 (2002).
9. Renaud, J. P. et al. Recombinant yeast in drug metabolism. Toxicology 82, 39-52 (1993).
10. Bachmann, K. A. & Ghosh, R. The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. Curr. Drug. Metab. 3, 299-314 (2001).
11. Testino, S. A. and Patonay, G. High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography tandem mass spectroscopy. J. Pharm. Biomed. Anal. 30, 1459-1467 (2003).
12. Mahmood, I. Interspecies scaling: predicting volumes, mean residence time and elimination half-life. Some considerations. J. Pharm. Pharmacol. 50, 493-499 (1998).
13. Jang, G. R., Harris, R. Z. & Lau, D. T. Pharmacokinetics and its role in small molecule drug discovery research. Med. Res. Rev. 21, 382-396 (2001).
14. Lesko, L. J., Rowland, M., Peck, C. C. & Blaschke, T. F. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Eur. J. Pharm. Sci. 10, iv-xiv (2000).
15. Mahmood, I. Allometric issues in drug development. J. Pharm. Sci. 88, 1101-1106 (1999).
16. Turteltaub, K. W. & Vogel, J. S. Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research. Curr. Pharm. Des. 6, 991-1007 (2000).
17. Aboagye, E. O., Price, P. M. & Jones, T. M. In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography. Drug Discov. Today 6, 293-302 (2001).
18. Turleltaub, K. W. et al. Accelerator mass spectrometry in biomedical dosimetry: relationship between low exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc. Natl Acad. Sci. USA 87, 5288-5292 (1990).
19. The European Agency for the Evaluation of Medical Products Evaluation of Medicines for Human Use. Position paper on the non-clinical safety studies to support clinical trials with a single low dose of a compound. CPMP/SWP/2599/02 draft [online], (cited 01.02.2003) < http://www.emea.eu.int/pdfs/human/swp/ 259902en.pdf> (2002).
20. IEH testing requirements under the EC White Paper 'Strategy for a future chemicals policy'. (Institute of Environment and Health, Leicester, UK, 2001).
21. IEH testing requirements under the EC White Paper 'Strategy for a future chemicals policy - an update' (Draft). (Institute of Environment and Health, Leicester, UK, 2001).
22. Mathieu, M. A closer look at screening INDs. Applied Clinical Trials, April, 1-2 (2001).
23. Young, G., Ellis, W., Ayrton, J., Hussey, E. and Adamkiewicz, B. Accelerator mass spectrometry (AMS) recent experience of its use in a clinical study and the potential future of the technique. Xenobiotica 31, 619-632 (2001).
24. Williams, P. et al. Accelerator mass spectrometry and microdosing to evaluate the clinical pharmacokinetics of a new agent. Clin. Pharmacol. Ther. 71, 75 (2002).
25. Hartvig, P., Bergström, M. and Långström, B. Use of positron emission tomography in analysing receptor function in vivo. Toxicol. Lett. 120, 243-251 (2001).
26. Cherry, S. R. Fundamentals of positron emission tomography and applications in preclinical drug development. J. Clin. Pharmacol. 41, 482-491 (2001).
27. Cunningham, V. J. et al. A method of studying pharmacokinetics in man at picolmolar drug concentrations. Br. J. Clin. Pharmacol. 32, 167-172 (1991).
28. Saleem, A. et al. Pharmacokinetic evaluation of N-(2-(dimethylamino)ethyl)acrideine-4-carboxamide in patients by positron emission tomography. J. Clin. Oncol. 19, 1421-1429 (2001).
29. Lappin, G. & Garner, R. C. In Handbook of Analytical Separations (ed. Smith, R. M.)(Elsevier, Amsterdam, in the press).
30. 4C-labelled -6-[amino(4-chlorophenyl)(1-methyl-1H-imidazole-5-yl)methyl]-4- (3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab. Dispos. 30, 823-829 (2002).
31. Gupta, N., Price, P. M. & Aboagye, E. O. PET for in vivo pharmacokinetic and pharmacodynamic measurements Eur. J. Cancer. 38, 2094-2107 (2002).